Prometheus Biosciences, Inc. Common Stock
RXDX
RXDX was delisted on the 15th of June, 2023.
103 hedge funds and large institutions have $1.04B invested in Prometheus Biosciences, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 27 increasing their positions, 30 reducing their positions, and 5 closing their positions.
580% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 5
39% more funds holding
Funds holding: 74 → 103 (+29)
4% more capital invested
Capital invested by funds: $1.01B → $1.04B (+$38.1M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
10% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$67.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$21.6M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$11.2M |
| 4 |
Goldman Sachs
New York
|
+$10.3M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$9.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$28.9M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$20.2M |
| 3 |
RI
RTW Investments
New York
|
-$20M |
| 4 |
O
OrbiMed
New York
|
-$9.88M |
| 5 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$7.91M |
RXDX Hedge Fund Activity: Q1 2022 in Review
103 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Prometheus Biosciences, Inc. Common Stock (RXDX) for Q1 2022, worth a combined $1.04B — up 3.8% from $1.01B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new RXDX positions and 5 closed out — a net gain of 29 holders — while 27 added to existing stakes and 30 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $67.8M. The largest seller was Perceptive Advisors, cutting an estimated $28.9M.
- 103 institutional investors held Prometheus Biosciences, Inc. Common Stock (RXDX) as of Q1 2022, up from 74 in Q4 2021.
- Funds reported $1.04B of Prometheus Biosciences, Inc. Common Stock stock for Q1 2022, up 3.8% quarter-over-quarter.
- 34 funds opened new Prometheus Biosciences, Inc. Common Stock positions in Q1 2022 and 5 closed out, a net change of +29 holders.
- The largest Prometheus Biosciences, Inc. Common Stock buyer in Q1 2022 was Boxer Capital, an estimated $67.8M added.
- The largest Prometheus Biosciences, Inc. Common Stock seller in Q1 2022 was Perceptive Advisors, an estimated $28.9M sold.
Based on aggregated 13F filings for Q1 2022.